At Motley Fool, Brian Orelli sizes up both Pacific Biosciences and Complete Genomics to determine which one is the "better buy." Orelli notes that some analysts are skeptical about sequencing's prospects, though he isn't since there is a demand for sequencing and because "the bust [is] still many years away." As for choosing between the two companies, Orelli says, "It's too early to make a definitive call, but of the two, I like PacBio better because I'm not fond of the low-cost, high-volume business model." There is also a poll going on over there, so let your thoughts be known.
Dec 01, 2010